Breaking News

Arranta Bio Unveils mRNA Vaccines Manufacturing Capability

Announces first end-to-end manufacturing for mRNA vaccines in its commercial-ready GMP facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Arranta Bio, a contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, unveiled plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines. Arranta will offer the first end-to-end platform for full integration of cGMP manufacturing of critical raw materials, in-vitro transcription, mRNA purification, LNP formulation and sterile fill/finish all within its Watertown, MA facility. Arranta intends to support product innovators using ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters